Efgartigimod Efficacy in Idiopathic Inflammatory Myopathy Today Argenx announced the results of their Phase 3 "ALKIVIA" study; demonstrating efficacy and safety of subcutaneous efgartigimod for Idiopathic Inflammatory Myopathy (IIM, AKA inflammatory myositis). https://t.co/TYP4KcdLoa